Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

R8404

Sigma-Aldrich

Rufinamide

≥98% (HPLC), powder

Sinonimo/i:

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C10H8F2N4O
Numero CAS:
106308-44-5
Peso molecolare:
238.19
Numero MDL:
MFCD00865314
Codice UNSPSC:
12352200
ID PubChem:
24724595
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

white

Solubilità

DMSO: 9 mg/mL

Ideatore

Novartis

Temperatura di conservazione

−20°C

Stringa SMILE

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
POGQSBRIGCQNEG-UHFFFAOYSA-N

Informazioni sul gene

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Azioni biochim/fisiol

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

Caratteristiche e vantaggi

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Implicazioni diagnostiche

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Pittogrammi

Exclamation markHealth hazard
GHS07,GHS08

Avvertenze

Warning

Indicazioni di pericolo

H336 - H351 - H361fd

Classi di pericolo

Carc. 2 - Repr. 2 - STOT SE 3

Organi bersaglio

Central nervous system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Lacosamide solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-029

Lacosamide solution

vibrant-m

Y0001982

Lacosamide

Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Sigma-Aldrich

Sigma-Aldrich

SML0936

Teriflunomide

Retigabine analytical standard

Supelco

90221

Retigabine

Gabapentin solid

Sigma-Aldrich

G154

Gabapentin

Streptavidin Sepharose™ High Performance Cytiva 17-5113-01, pack of 5 mL

GE17-5113-01

Streptavidin Sepharose™ High Performance

K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Emma D Deeks et al.
CNS drugs, 20(9), 751-760 (2006-09-07)
Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures
Paul L McCormack
PharmacoEconomics, 30(3), 247-256 (2012-02-16)
Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy
Marc R Suter et al.
Anesthesiology, 118(1), 160-172 (2012-12-12)
Voltage-gated sodium channels dysregulation is important for hyperexcitability leading to pain persistence. Sodium channel blockers currently used to treat neuropathic pain are poorly tolerated. Getting new molecules to clinical use is laborious. We here propose a drug already marketed as
Rainer Schimpf et al.
Heart rhythm, 9(5), 776-781 (2012-01-17)
The arrhythmogenic potential of short QT intervals has recently been highlighted in patients with a short QT syndrome. Drug-induced QT-interval prolongation is a known risk factor for ventricular tachyarrhythmias. However, reports on drug-induced QT-interval shortening are rare and proarrhythmic effects
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.